[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100424401":3},{"organization":4,"armGroups":7,"interventions":8,"overallOfficials":7,"centralContacts":13,"locations":19,"responsibleParty":40,"collaborators":7,"id":42,"slug":43,"hasResults":44,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":7,"eligibilityCriteria":48,"healthyVolunteers":44,"sex":49,"minAge":50,"maxAge":7,"enrollmentInfo":51,"targetDuration":7,"studyType":54,"phases":55,"briefSummary":57,"conditions":58,"keywords":7,"overallStatus":22,"whyStopped":7,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":70},{"fullName":5,"class":6},"Naestved Hospital","OTHER",null,[9],{"type":10,"name":11,"description":12,"armGroupLabels":7,"otherNames":7},"DIAGNOSTIC_TEST","meassurement of PD-L1, ALK, EGFR","PD-L1 test will be performed on cell-blocks using PD-L1 antibodies 22C3 and staining platform Dako Omnis (Agilent, Glostrup -Denmark).\n\nALK test will be performed on cell-blocks using staining platform Dako Omnis (Agilent, Glostrup- Denmark) and ALK antibodies \"Origene\" clone: OT1A4. Sample quality is assessed as for PD-L1.\n\nEGFR mutation analysis will be performed as follows: after tumor content evaluation of hematoxylin and eosin stained slides, relevant regions are macrodissected and subjected to a standard genomic DNA extraction procedure using the GeneRead DNA FFPE Kit (Qiagen). Samples will be analysed using the GeneRead QIAact Actionable Insights Tumor Panel (Qiagen)",[14],{"name":15,"role":16,"phone":17,"phoneExt":7,"email":18},"Katrine Fjaellegaard, MD","CONTACT","31924375","kafj@regionsjaelland.dk",[20],{"facility":21,"status":22,"city":23,"state":24,"zip":25,"country":26,"countryCode":27,"cosmosGeoPoint":28,"geoPoint":33,"contacts":34},"Næstved Sygehus, department of pulmonary medicine","RECRUITING","Næstved","Region Sjælland","4700","Denmark","DK",{"type":29,"coordinates":30},"Point",[31,32],11.76092,55.22992,{"lat":32,"lon":31},[35,38],{"name":36,"role":16,"phone":37,"phoneExt":7,"email":18},"katrine fjællegaard, MD","20864959",{"name":39,"role":16,"phone":7,"phoneExt":7,"email":7},"Uffe Bødtger, MD, PhD",{"type":41,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR","100424401","oncodrivers-in-malignant-pleural-effusions-associated-with-non-small-cell-lung-cancer-a-prospective-study-100424401",false,"NCT04806412","Oncodrivers in Malignant Pleural Effusions Associated With Non-small Cell Lung Cancer: A Prospective Study.","The Prevalence of Oncodrivers in Malignant Pleural Effusions Associated With Non-small Cell Lung Cancer: A Prospective Study.","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Pleural effusion known or suspected of association with NSCLC (pleural fluid cytology positive for cells from NSCLC)\n* Patients must be able to give informed consent\n\nExclusion Criteria:\n\n* Full oncodriver status measured in any pleural fluid in current work-up\n* Inability to understand written or spoken Danish.","ALL","18 Years",{"count":52,"type":53},100,"ESTIMATED","INTERVENTIONAL",[56],"NA","Oncological treatment of patients with disseminated non-small cell lung cancer (NSCLC) is depending on the status of programmed death-ligand 1 (PD-L1), anaplastic lymphoma kinase (ALK) and epidermal growth factor receptor (EGFR), so called oncodrivers. These can be measured in pleural fluid, but the prevalence is uncertain. In a prospective study, the research team aim to measure PD-L1, ALK and EGFR in patients with pleural fluid cytology positive for NSCLC to report the prevalence. Also, the study will investigate if the chance of obtaining oncodriver status is depending on the volume analysed and how the lack of oncodrivers influence the following work-up.",[59,60],"Malignant Pleural Effusion","Non-small Cell Lung Cancer","2026-06-19",{"date":63,"type":64},"2026-06-24","ACTUAL",{"date":66,"type":64},"2021-03-15",{"date":68,"type":53},"2028-12-31",{"name":5,"class":6},1]